iLite® CD20 (-) Target
BM5015
CD20-negative iLite® target cells are ideal for use as controls in CD20-specific bioactivity assays.
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
Product Overview
iLite® Target CD20 (-) Assay Ready Cells are depleted of CD20 expression. They are designed to be used as a control for unspecific activation of ADCC and ADCP that can be a confounding factor when performing ADCC or ADCP assays.
iLite Target CD20 (-) Assay Ready Cells are based on a human B lymphocyte cell line, Raji (ATCC# CCL-86), and have been genetically engineered and optimized to be depleted of CD20 expression.
iLite® Target CD20 (-) Assay Ready Cells are to be use as negative controls together with iLite ADCC and ADCP Effector Assay Ready Cells and iLite Target CD20 (+) Assay Ready Cells for measuring the ADCC and ADCP activity of anti-CD20 antibodies.
FOR RESEARCH USE ONLY
How it works
Principle of iLite® ADCC and ADCP Bioassays
Our two-cell ADCC or ADCP bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (for ADCC) or FcγRIIa (for ADCP) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.
What's in the box?
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM5015 |
| Assay target | ADCC ADCP CD20 |
| Size | 1 vial corresponding to one 96 well plate |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Application Note
